BioCryst Net Working Capital from 2010 to 2024
| BCRX Stock | USD 4.43 0.07 1.56% |
Net Working Capital | First Reported 2010-12-31 | Previous Quarter 346 M | Current Value 252.2 M | Quarterly Volatility 150.1 M |
Check BioCryst Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioCryst main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 113.7 M or Selling General Administrative of 209.6 M, as well as many exotic indicators such as Price To Sales Ratio of 3.3, Dividend Yield of 0.0 or Days Sales Outstanding of 59.59. BioCryst financial statements analysis is a perfect complement when working with BioCryst Pharmaceuticals Valuation or Volatility modules.
BioCryst | Net Working Capital |
Latest BioCryst Pharmaceuticals' Net Working Capital Growth Pattern
Below is the plot of the Net Working Capital of BioCryst Pharmaceuticals over the last few years. It is BioCryst Pharmaceuticals' Net Working Capital historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioCryst Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Net Working Capital | 10 Years Trend |
|
Net Working Capital |
| Timeline |
BioCryst Net Working Capital Regression Statistics
| Arithmetic Mean | 147,404,150 | |
| Geometric Mean | 95,468,899 | |
| Coefficient Of Variation | 101.82 | |
| Mean Deviation | 127,028,867 | |
| Median | 50,555,000 | |
| Standard Deviation | 150,086,589 | |
| Sample Variance | 22526T | |
| Range | 417.5M | |
| R-Value | 0.76 | |
| Mean Square Error | 10120.7T | |
| R-Squared | 0.58 | |
| Significance | 0.0009 | |
| Slope | 25,620,456 | |
| Total Sum of Squares | 315363.8T |
BioCryst Net Working Capital History
About BioCryst Pharmaceuticals Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include BioCryst Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. BioCryst Pharmaceuticals investors use historical funamental indicators, such as BioCryst Pharmaceuticals's Net Working Capital, to determine how well the company is positioned to perform in the future. Although BioCryst Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in BioCryst Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on BioCryst Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on BioCryst Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in BioCryst Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Working Capital | 346 M | 252.2 M |
Pair Trading with BioCryst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with BioCryst Stock
| 0.69 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against BioCryst Stock
| 0.72 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
| 0.48 | MRKR | Marker Therapeutics | PairCorr |
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of BioCryst Pharmaceuticals Correlation against competitors. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.